Comparative Pharmacology

Head-to-head clinical analysis: CLOPRA versus PROMETHAZINE.

Peer-Reviewed Evidence

Differential Analysis

CLOPRA vs PROMETHAZINE

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

CLOPRA

Antiemetic/Prokinetic Agent

Category C

PROMETHAZINE

Antihistamine / Antiemetic

Category A/B

Head-to-Head

Clinical Matrix

Mechanism of Action

Clopra (metoclopramide) is a dopamine D2 receptor antagonist and a 5-HT4 receptor agonist, enhancing gastrointestinal motility and having antiemetic effects via central and peripheral actions.

Promethazine is a phenothiazine derivative that acts as a potent histamine H1 receptor antagonist, thereby blocking the effects of histamine. It also has central anticholinergic, antiemetic, and sedative properties, likely mediated through antagonism at muscarinic, dopamine D2, and serotonin receptors in the brain.

Clinical Dosing

Clopra (metoclopramide) 10 mg orally or intramuscularly 30 minutes before meals and at bedtime; maximum 30 mg/day. For intravenous administration, give 10 mg over 1-2 minutes.

12.5-25 mg IM or IV every 4-6 hours; also 25 mg PO or PR every 6-8 hours. Maximum 100 mg/day.

Direct Interaction

MODERATE Risk

Other Significant Interactions

Clinical Note

moderate

Metoclopramide + Haloperidol

"The risk or severity of adverse effects can be increased when Metoclopramide is combined with Haloperidol."

Clinical Note

moderate

Promethazine + Risedronic acid

"Promethazine can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects."

Clinical Note

moderate

Promethazine + Methylphenidate

"Promethazine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects."

Clinical Note